Genprex (GNPX) News Today $0.29 +0.03 (+12.84%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.28 -0.01 (-3.33%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GNPX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Genprex files to sell 25M shares of common stock for holdersSeptember 12 at 9:10 PM | msn.comGenprex Stockholders Approve Key Proposals at Annual MeetingSeptember 3, 2025 | theglobeandmail.comGenprex to Present and Participate at Upcoming September Investor and Industry ConferencesSeptember 2, 2025 | prnewswire.comGenprex receives notice of allowance for multiple patents for ReqorsaAugust 18, 2025 | msn.comGenprex Secures Patent Allowances for Gene TherapyAugust 18, 2025 | tipranks.comGenprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat CancersAugust 18, 2025 | prnewswire.comGenprex Issues Stockholder Letter and Provides 2025 Corporate UpdateAugust 4, 2025 | prnewswire.comGenprex, Inc. (GNPX) Latest Stock News & Headlines - Yahoo FinanceJune 27, 2025 | finance.yahoo.comGenprex reports positive results from diabetes gene therapy studyJune 25, 2025 | investing.comGenprex Announces Positive Preclinical Results for GPX-002June 24, 2025 | tipranks.comGenprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific SessionsJune 24, 2025 | prnewswire.comGenprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific SessionsJune 23, 2025 | prnewswire.comGenprex to Participate at BIO 2025 International ConventionJune 3, 2025 | prnewswire.comGenprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual MeetingMay 29, 2025 | prnewswire.comGenprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual MeetingMay 28, 2025 | prnewswire.comGenprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 DiabetesMay 7, 2025 | prnewswire.comGenprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of GlioblastomaMay 6, 2025 | prnewswire.comGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual MeetingApril 30, 2025 | prnewswire.comGenprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual MeetingApril 29, 2025 | prnewswire.comGenprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of MesotheliomaApril 28, 2025 | prnewswire.comGenprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual MeetingApril 24, 2025 | prnewswire.comGenprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement ProceedingsApril 22, 2025 | prnewswire.comGenprex reports progress in lung cancer gene therapyMarch 28, 2025 | uk.investing.comGenprex to present results preclinical data from Reqorsa studyMarch 27, 2025 | markets.businessinsider.comGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual MeetingMarch 26, 2025 | prnewswire.comGenprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific SessionsMarch 25, 2025 | prnewswire.comCS Diagnostics (OTCQB: CSDX) CS-Protect Hydrogel FDA Approval on Fasttrack – GNPX, BON, SES, BETRF – Stocks to Watch Now!March 18, 2025 | theglobeandmail.comGenprex to Participate at BIO Europe Spring 2025March 4, 2025 | prnewswire.comGenprex announces advancement of diabetes program, strategic collaborationFebruary 19, 2025 | markets.businessinsider.comGenprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery SystemFebruary 19, 2025 | prnewswire.comGenprex announces advancement of its diabetes gene therapy programFebruary 18, 2025 | markets.businessinsider.comGenprex Provides Update on Diabetes Gene Therapy ProgramFebruary 18, 2025 | prnewswire.comGenprex’s Oncoprex included in lung cancer therapyFebruary 13, 2025 | markets.businessinsider.comGenprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung CancerFebruary 13, 2025 | prnewswire.comGenprex faces Nasdaq delisting over stock price, equity issuesFebruary 12, 2025 | msn.comGenprex doses first subject in expansion part of lung cancer gene therapy trialJanuary 24, 2025 | msn.comGenprex announces first patient dosed with Regorsa in Phase 2 lung cancer studyJanuary 24, 2025 | markets.businessinsider.comGenprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerJanuary 23, 2025 | prnewswire.comGenprex to Participate at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | prnewswire.comGenprex receives Safety Review Committee approval to advance Acclaim-3 trialDecember 17, 2024 | markets.businessinsider.comGenprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung CancerDecember 16, 2024 | prnewswire.comGenprex signs exclusive license agreement with University of MichiganNovember 20, 2024 | markets.businessinsider.comGenprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung CancerNovember 20, 2024 | prnewswire.comGenprex to present positive preclinical data from Reqorsa Gene Therapy studyNovember 6, 2024 | markets.businessinsider.comGenprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual MeetingNovember 5, 2024 | prnewswire.comGenprex to Participate in 2024 BIO Europe ConferenceOctober 31, 2024 | prnewswire.comLooking Into Genprex's Recent Short InterestOctober 30, 2024 | benzinga.comGenprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and GlioblastomaOctober 28, 2024 | prnewswire.comGenprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK PositiveOctober 24, 2024 | prnewswire.comGenprex (NASDAQ:GNPX) Stock Quotes, Forecast and News SummaryOctober 22, 2024 | benzinga.com Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNPX Media Mentions By Week GNPX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNPX News Sentiment▼0.500.93▲Average Medical News Sentiment GNPX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNPX Articles This Week▼31▲GNPX Articles Average Week Get the Latest News and Ratings for GNPX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Genprex and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SONN News Today AKTX News Today LIXT News Today AYTU News Today QTTB News Today CTXR News Today ABP News Today LSTA News Today CING News Today IXHL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GNPX) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone thought he was insane…SpaceX just struck a $17 billion deal with EchoStar for radio frequencies, and tech analyst Jeff Brown says it...Brownstone Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
